World News
Investing
Economy
Politics
Editor’s Pick

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

by June 4, 2025

by June 4, 2025

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0 comment

0

Facebook Twitter Pinterest Email

previous post

5 Biggest Blockchain ETFs in 2025

next post

Mali Court Adjourns Barrick’s Gold Complex Hearing Over Deepening Taxes, Control Dispute

You may also like

Mali Court Adjourns Barrick’s Gold Complex Hearing Over...

June 4, 2025

Adam Rozencwajg: Gold Stock Gains, Silver and Uranium...

June 4, 2025

5 Biggest Blockchain ETFs in 2025

June 4, 2025

Operational Update

June 4, 2025

Canadian Wildfires Force Mining Sector to Retreat as...

June 3, 2025

Crypto Market Recap: Circle Targets US$7.2 Billion IPO,...

June 3, 2025

West High YieldResources Ltd. Announces Proceeds from Exercise...

June 3, 2025

Top 10 Uranium-producing Countries

June 3, 2025

Development update – Collie graphite micronising facility

June 3, 2025

Lithium Universe LtdSpodumene Offtake Update

June 2, 2025

Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!

Your name
Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

About us
Contacts
Privacy Policy
Terms and Conditions
Email Whitelisting

Disclaimer: targetlinenews.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 targetlinenews.com | All Rights Reserved

World News
Investing
Economy
Politics
Editor’s Pick